clinical pathology testing. Many of the testing requirements are similar for every country, but others are not. The similarities and differences among several of the guidelines are discussed, and specific instances of ambiguous or inappropriate testing requirements are cited.
INTRODUCTION
This paper will present an overview of current global guidelines for preclinical safety assessment studies. It will include discussions of guidelines for hematology, clinical chemistry, and urinalysis with a focus on the similarities and differences among the various regulatory bodies. The paper will also include some personal observations on the scientific merit of these guidelines. For instance, I propose that we all agree to eliminate omithine decarboxylase from the clinical chemistry lists of all future guidelines because this test is inappropriate and apparently crept into the current lists by mistake.
The principal regulatory guidelines discussed in this paper include the following: the United States' Food and Drug Administration's (FDA) Red Book guidelines for direct food additives and color additives ; the United States' Environmental Protection Agency's (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) guidelines for pesticides ; the United States' EPA Toxic Substances Control Act (TSCA) guidelines for other chemicals; the Organization for Economic Cooperation and Development (OECD) guidelines for chemicals; Japan's Ministry of Health and Welfare (MOHW) guidelines for pharmaceuticals; and Japan's Ministry of Agriculture, Forestry, and Fisheries (MAFF) guidelines for agricultural chemicals. Brief mention will be made of Canada's Health and Welfare guidelines for pharmaceuticals, the European Community's (EC) guidelines for pharmaceuticals, and the United States' Center for Veterinary Medicine guidelines for target animal toxicity studies. Table I lists the type of studies, requiring clinical pathology testing, that are described in some of the regulatory guidelines. Only the FDA Red Book has separate guidelines for individual species. Although the hematology and clinical chemistry profiles do not change between rodents and dogs, the timing for the tests are different. Other regulatory bodies do not have separate species-specific guidelines, but they do indicate differences between the species for the timing of sample collection.
It is important to note that clinical pathology is not required or recommended for acute or singledose toxicity studies by any of the current guidelines. This is unfortunate, in my opinion, because a great deal can be learned about potential toxicities in these studies that often use higher doses than do longer studies. The absence of specific regulatory requirements for clinical pathology tests in acute studies should not be interpreted as an indictment of their value.
HEMATOLOGY
The hematology test recommendations are similar for most of the guidelines (Table II ). In general, the guidelines indicate that these tests &dquo;should be&dquo; done or are &dquo;considered to be appropriate&dquo; for all studies. Red Book, FIFRA, TSCA, and OECD guidelines list the parameters traditionally measured as a &dquo;complete blood count&dquo;: red blood cell count, hemoglobin, hematocrit, and total and differential white blood cell count. In addition, they also request a &dquo;... measure of clotting potential such as clotting time, prothrombin time, thromboplastin time, or platelet count ....&dquo; Because each of these tests measures a different aspect of coagulation, this section of the guidelines could be improved. I sug-gest that platelet count always be determined for all species, and that prothrombin time (PT) and activated partial thromboplastin time (APTT) be determined for dogs and nonhuman primates. There are technical and operational problems associated with coagulation testing in rodents, but when indicated, these tests can be successfully performed.
MOHW guidelines list the following for hematology parameters &dquo;usually examined&dquo;: red blood cell count, hemoglobin, hematocrit, total and differential white blood cell count, and platelet count, but they also state, &dquo;in addition, reticulocytes, PT, APTT, etc.&dquo; The &dquo;etc.&dquo; affects clinical pathologists and other laboratory professionals attempting to meet these guidelines, since it is not clear what is meant. MAFF guidelines have a similar statement. Although their test list does not include reticulocyte count, PT, or APTT, it does use &dquo;etc.&dquo;
CLINICAL CHEMISTRY
With respect to clinical chemistry, many of the guidelines (FDA Red Book, FIFRA, TSCA, and OECD) have the same general statements: &dquo;... areas appropriate to all studies are electrolyte balance, carbohydrate metabolism, liver and kidney func-tion&dquo; and &dquo;... other determinations which may be necessary ... include lipids, hormones, acid/base balance, methemoglobin, cholinesterase ....&dquo; In the new EC guidelines, there is this interesting and particularly appropriate statement: &dquo;Selection of techniques used and the choice of other tests should be appropriate to the current state of knowledge and to the animal species being used.&dquo; Agreement is needed among clinical pathologists and clinical chemists on what constitutes &dquo;appropriate&dquo; and what does not. Each laboratory has opinions, but a process for reaching a scientific consensus is needed.
Once again, MOHW guidelines have a statement that is problematic: &dquo;... it is desirable to include as many parameters as possible.&dquo; While this was certainly written with good intentions, it is very dif- Book has a fairly typical profile with &dquo;suggested de-terminations&dquo; being glucose, total protein, albumin, urea nitrogen, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase (GGT), calcium, phosphorus, sodium, potassium, chloride, and, as previously mentioned, omithine decarboxylase. FIFRA guidelines do not include GGT or omithine decarboxylase but do include creatine kinase (CK) for chronic studies. The scientific rationale for adding CK to chronic studies is not immediately obvious. TSCA guidelines include both GGT and omithine decarboxylase, as well as CK and cholesterol for chronic studies. Cholesterol is extremely variable in older rats with naturally occurring diseases, and I personally do not believe that inclusion of this test in chronic rodent studies is beneficial.
The OECD guidelines are very similar to TSCA. Their chronic study guidelines have a less complete profile but state, &dquo;Plasma is prepared from these samples and the following determinations are made:
... glucose ... urea nitrogen ... total protein, albumin ... liver function tests such as alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, omithine decarboxylase, ....&dquo; These are the only guidelines that mention the use of plasma for clinical chemistry testing, and most would agree that the liver enzyme activities are not true function tests.
MOHW has included a few additional tests in their list of &dquo;parameters usually examined.&dquo; Along with total protein and albumin, the guidelines include A:G ratio, a value easily calculated, and &dquo;protein fractions.&dquo; This is widely assumed to mean serum protein electrophoresis. Serum protein electrophoresis is useful for investigating abnormalities in total protein or, more specifically, globulin. If globulin is increased and causes of a polyclonal gammopathy have been ruled out clinically, an electrophoresis might be used to investigate the possibility of a monoclonal gammopathy. I know of no examples of a xenobiotic-induced monoclonal gammopathy. While some test materials might alter individual proteins, such as carrier proteins, I do not believe the alteration would be detected by serum protein electrophoresis. It is too insensitive to identify the specific proteins affected. Therefore, I see no rationale for performing this difficult, expensive, and time-consuming test on a routine basis in preclinical safety assessment. If necessary, it could be used to further explore an effect on globulin proteins, but I do not believe its use as a screening test is justified. MOHW also lists cholesterol, triglycerides, and alkaline phosphatase (instead of GGT) in its chemistry profile. As with its hematology test list, &dquo;etc.&dquo; is included at the end. MAFF has a smaller test list that &dquo;should be carried out,&dquo; but it also uses &dquo;etc.&dquo; at the end.
URINALYSIS
Guideline recommendations for urinalysis are quite variable. The FDA Red Book states that urinalysis is considered to be of limited value for routine short-term and long-term studies in rodents and dogs. FIFRA, TSCA, and OECD guidelines state that urinalysis is not required on a routine basis unless there is an &dquo;... indication based on expected or known toxicity ....&dquo; These guidelines do state that urinalysis &dquo;should be done&dquo; for chronic studies. I believe that urinalysis at the end of a chronic rat study does not provide useful information because of the high incidence of chronic progressive nephropathy in rats.
When recommended, the urinalysis test requirements are fairly routine and generally include appearance, volume (16-24 hr), specific gravity, reagent strip chemistry tests (e.g., pH, glucose, ketones, protein, occult blood, bilirubin, urobilinogen), and sediment microscopy. There are subtle differences, however, and these occur primarily in the reagent strip tests.
MOHW and MAFF guidelines state that urinalysis should be done. MOHW guidelines, however, include urinary &dquo;electrolytes (Na, K, etc.).&dquo; They do not specify what type of measurement is required (e.g., electrolyte concentration, 24-hr electrolyte excretion, fractional clearance of electrolyte). The value of any of these measures as a screening test for renal toxicity is questionable. Urinary electrolyte concentration varies with water and food consumption as a normal consequence of electrolyte homeostasis.
CARCINOGENICITY
The scientific rationale for some of the requirements for clinical pathology testing in carcinogenicity testing is not clear. For example, FIFRA guidelines require differential leukocyte counts at 12 and 18 mo and at termination on 10 animals/sex/ group. If the purpose of hematology in a carcinogenicity study is to detect leukemia, then examining the blood of only 10 animals/sex/group is akin to trying to identify hepatocellular carcinoma by examining the livers of only 10 animals/sex/group. For the FDA Red Book, &dquo;erythrocyte counts and total differential leukocyte counts should be made at 6, 12, and 18 months and prior to terminal sacrifice for all animals ....&dquo; That would include animals sacrificed due to poor health or a moribund condition. TSCA, OECD, and MAFF guidelines are fairly similar. Blood smears for differential leukocyte counts (total leukocyte counts are not required) are made from all animals at 12 and 18 mo and at termination. FIFRA, TSCA, OECD, MAFF, and MOHW all request differentials for animals that experience a &dquo;deterioration of health.&dquo; A deterioration of health is usually interpreted as animals that are sacrificed because of poor health.
The MOHW carcinogenicity study guidelines seem to be the most scientifically based. Red and white blood cell counts are to be done and blood smears prepared for all animals at the time of sacrifice, including animals that are moribund. The blood smears are to be examined only in cases &dquo;... suggestive of blood disorders such as anemia, hypertrophy of lymph nodes, swelling of liver and spleen, etc.&dquo; Because the selection of animals for blood smear examination is somewhat subjective, my preference would be to examine blood smears only from those animals for which the anatomical pathologist is attempting to differentiate between leukemia and a leukemoid reaction. The blood smear could be reviewed for evidence of leukemia as an adjunct to the histopathologic examination for making a final diagnosis.
None of the carcinogenicity guidelines require hemoglobin, hematocrit, red blood cell indices, or platelet count, but all of these parameters are automatically measured when samples are analyzed by most automated hematology analyzers and should be reported.
GENERAL COMMENTS
The new EC guidelines state that &dquo;Control data from the colony are necessary for small mammals ....&dquo; To my knowledge, this is the only guideline that says something of this nature. It is not entirely clear if the guideline is referring to historical reference ranges or to data from concurrent control groups within the study.
The Canadian preclinical testing guidelines were revised in 1990. The new guidelines do not have a series of test lists but do state that, &dquo;Occult fecal blood and hepatic and renal function tests should be done where applicable.&dquo; This is the only mention of occult fecal blood in preclinical safety assessment guidelines. Although examples of hepatic function tests are not given, total bile acids may be appropriate. Bromsulphalein clearance studies have been used in the past, but the dye is no longer commercially available for diagnostic use in the United
States.
The guidelines provided by the Center for Veterinary Medicine for target animal toxicity studies need revision. For example, the guidelines for the cow suggest that serum amylase activity be considered, but the enzyme has no utility in this species. Lactate dehydrogenase (LDH) isoenzymes are suggested for dog and cat target animal toxicity studies. LDH isoenzymes are of no practical value as a screening test, and in my opinion, clinical pathology requirements for preclinical safety assessment studies should be developed as screening profiles.
